Lymphocyte Engineering Becomes a Reality
It is our pleasure to invite you to the 3rd International Conference on Lymphocyte Engineering.
Great strides have been made in recent years in the engineering of lymphocytes for the treatment of cancer, autoimmune diseases, pathogenic diseases and primary immune deficiencies. Combining gene therapy, cell therapy and immune therapy, the emerging field of lymphocyte engineering employs cutting edge technologies of viral and non-viral vectorology, genome editing and protein design as well as advanced clinical protocols for cell harvest, expansion and re-infusion. With groundbreaking clinical success leading to FDA approved products and with vibrant, exponentially growing research, lymphocyte engineering is the wave of the future.
Still, the challenges are formidable and the stakes are high. Realizing the full promise of lymphocyte engineering will require the combined efforts of a dedicated community. ICLE 2022 will facilitate the sharing of data and ideas, promote collaborations, and address common challenges to advance clinical translation. It will provide an effective environment for active learning, discussions of real-world case studies and for networking between like-minded peers.
Whether you are a scientist, clinical researcher, part of a start-up or an established industry company, ICLE 2022 is your opportunity to network and discuss immuno-gene therapy with those as excited and passionate about this innovative treatment modality.
See you in Munich!
On behalf of the Scientific Committee,
Adi Barzel, PhD
ICLE Conference Co-chair;
President, the Israeli Society for Gene and Cell Therapy (ISGCT);
Senior Lecturer, Tel-Aviv University
Dirk Busch, MD
ICLE Conference Co-Chair;
Director at the Institute for Med. Microbiology,
Immunology and Hygene Technical University of Munich, Germany